Novartis Ag (NVS) EBT Margin (2009 - 2025)

Novartis Ag (NVS) has 15 years of EBT Margin data on file, last reported at 32.24% in Q2 2025.

• Quarterly EBT Margin rose 154.0% year-over-year to 32.24% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 28.08% (down 1075000.0% YoY) and the FY2025 annual result came in at 29.99%, up 288.0% from the prior year.
• EBT Margin advanced to 32.24% in Q2 2025 per NVS's latest filing, from 28.63% in the prior quarter.
• The five-year high for EBT Margin was 13229930.74% in Q1 2022, with the low at 15.98% in Q2 2022.
• Average EBT Margin over 5 years is 1085738.53%, with a median of 31.47% recorded in 2024.
• Year-over-year, EBT Margin surged 1322959907 bps in 2022 and sank 1168642426 bps in 2023.
• Novartis Ag's EBT Margin stood at 23.48% in 2021, then surged by 7799 bps to 1854.72% in 2022, then plunged by 99 bps to 23.36% in 2023, then rose by 23 bps to 28.63% in 2024, then increased by 13 bps to 32.24% in 2025.
• Business Quant data shows NVS's EBT Margin at 32.24% in Q2 2025, 28.63% in Q4 2024, and 30.7% in Q2 2024.